Shots: The US FDA has granted Emergency Use Authorization (EUA) for its rapid point-of-care BD Veritor SARS-CoV-2 Assay which allows the result in 15 mins evaluated in 20 sites across the US with 84% sensitivity and 100% specificity. Additionally, BD plans for increasing capacity to produce 2M tests per week by the end of September […]Read More
Shots: Chembio to receive funding if reaches certain milestones, to develop POC test utilizing Chembio’s DPP platform and hand-held optical analyzer. The POC test will be built upon Takeda’s biomarker and is expected to provide results in ~15 mins. from a 10µL drop of fingerstick blood The collaboration is to combine Chembio’s DPP platform and […]Read More
Shots: ChemBio will be using its patented DPP® technology platform to test rapid HCV core antigen assay Parallely, FIND is conducting pilot studies in six countries to introduce novel algorithms and demonstrate the impact of HCV rapid diagnostics FIND plans to assess the outcomes of the feasibility studies in Dec’18 and fund one company for […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
